The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.
 
Paolo Nuciforo
No Relationships to Disclose
 
Dominik Hlauschek
Research Funding - Genentech/Roche (Inst)
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Genomic Health; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Synthon
Research Funding - AstraZeneca (Inst); Genentech (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche; Roche
 
Evandro de Azambuja
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - AstraZeneca (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst); Servier/Pfizer (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech
 
Roberta Fasani
No Relationships to Disclose
 
Patricia Villagrasa
No Relationships to Disclose
 
Karoline Muehlbacher
Research Funding - Genentech (Inst)
 
Christos Sotiriou
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; CEPHEID; Puma Biotechnology; Seagen; Vertex
Speakers' Bureau - Eisai; Foundation Medicine; Prime Oncology; Teva
Patents, Royalties, Other Intellectual Property - A companion diagnostic for CDK4/CDK6 inhibitory drugs based on CDK4 Phosphorylation. Which patient to be treated and how. PCT/EP2017/061780; Epigenetic portraits of human Breast Cancer, PCT/EP2012/050836, WO2012/098215
Travel, Accommodations, Expenses - Roche; Roche/Genentech; Roche/Genentech
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; NanoString Technologies (Inst); Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics
 
Georg Pfeiler
Honoraria - Amgen; AstraZeneca; Bondimed; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bondimed; Novartis; Pfizer; Roche
 
Florentine Hilbers
Research Funding - Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Timothy R. Wilson
Employment - Genentech
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Genentech
 
Junko Aimi
Employment - Genentech
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Genentech
 
Thomas Stout
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Vicente Valero
No Relationships to Disclose
 
Christian Fesl
Research Funding - Genentech (Inst)
 
Jose Baselga
Leadership - Bristol-Myers Squibb; Foghorn Therapeutics; Infinity Pharmaceuticals; Varian Medical Systems
Stock and Other Ownership Interests - Apogen Biotechnologies; Aura Biosciences; GRAIL; Juno Therapeutics; Northern Biologics; PMV Pharma; Tango Therapeutics; venthera
Consulting or Advisory Role - Novartis
Patents, Royalties, Other Intellectual Property - Combination Therapy Using PDK1 And PI3K Inhibitors.; INHIBITION OF KMT2D FOR THE TREATMENT OF CANCER; Use Of Phosphoinositide 3-Kinase Inhibitors For Treatment Of Vascular Malformations
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche
 
Michael Gnant
Employment - Sandoz (I)
Honoraria - Amgen; AstraZeneca; Celgene; Lilly; Medison; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Lilly
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Ipsen; Lilly; Medtronic; Pfizer; Roche/Genentech
 
Martine Piccart
Leadership - Radius Health
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Crescendo Biologics; Debiopharm Group; G1 Therapeutics; HUYA Bioscience International; Immunomedics; Lilly; Menarini; MSD; Novartis; Odonate Therapeutics; Oncolytics; Periphagen; Pfizer; PharmaMar; Roche; Seagen
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche (Inst); SERVIER (Inst); Synthon (Inst)
 
Fabrice Andre
Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche